Cited by 2,688CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchImmunotherapy and Immune Responses

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Open access

Park, Jae H., Rivière, Isabelle, Gonen, Mithat, Wang, Xiuyan, Sénéchal, Brigitte, Curran, Kevin J., Sauter, Craig, Wang, Yongzeng, Santomasso, Bianca, Mead, Elena, Roshal, Mikhail, Maslak, Peter, Davila, Marco, Brentjens, Renier J., Sadelain, Michel·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1709919PMC PMC6637939

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1709919

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citation
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citation
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citation
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914

Show all 24 references

Sorted by citations

Items 201–300 of 1,004

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Guedan, S., & Alemany, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02460 · Cited by 158
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Brændstrup, P., Levine, B. L., & Ruella, M. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2019.12.004 · Cited by 163
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
Gökbuget, N., Boissel, N., Chiaretti, S., Dombret, H., Doubek, M., Fielding, A. K., Foà, R., Giebel, S., Hoelzer, D. F., Hunault, M., et al. (2024) · Blood · doi:10.1182/blood.2023023568 · Cited by 158
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Zhao, Q., Jiang, Y., Xiang, S., Kaboli, P. J., Shen, J., Zhao, Y., Wu, X., Du, F., Li, M., Cho, C. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658753 · Cited by 150
Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
Zhou, J., Jin, L., Wang, F., Zhang, Y., Liu, B., & Zhao, T. (2019) · Protein & Cell · doi:10.1007/s13238-019-0643-y · Cited by 151
Cancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 151
Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity
Cazaux, M., Grandjean, C. L., Lemaı̂tre, F., Garcia, Z., Beck, R. J., Milo, I., Postat, J., Beltman, J. B., Cheadle, E. J., & Bousso, P. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182375 · Cited by 152
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
Bedoya, D. M., Dutoit, V., & Migliorini, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640082 · Cited by 151
Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
Schneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L. M., Steimle, B. L., Mahmud, H., Anthony-Gonda, K., Krueger, W. H., Zhu, Z., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6401 · Cited by 152
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadiñanos-Garai, A., Vispute, K., Bosshard‐Carter, L., Mitsikakou, M., Mehra, V., Roddy, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00917 · Cited by 151
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 154
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
Riegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 148
Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial
Jiang, H., Li, C., Yin, P., Guo, T., Liu, L., Xia, L., Wu, Y., Zhou, F., Ai, L., Shi, W., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25582 · Cited by 148
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1457 · Cited by 147
Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions
Bagley, S. J., & O’Rourke, D. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107419 · Cited by 147
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148
Co-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 149
Toxicities of CD19 CAR‐T cell immunotherapy
Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 144
T cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 145
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 142
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
Alcantara, M., Tesio, M., June, C. H., & Houot, R. (2018) · Leukemia · doi:10.1038/s41375-018-0285-8 · Cited by 142
Cytokine release syndrome: grading, modeling, and new therapy
Liu, D., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0653-x · Cited by 141
A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
John, S., Chen, H., Deng, M., Gui, X., Wu, G., Chen, W., Li, Z., Zhang, N., An, Z., & Zhang, C. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.001 · Cited by 143
History of hematopoietic cell transplantation: challenges and progress
Granot, N., & Storb, R. F. (2020) · Haematologica · doi:10.3324/haematol.2019.245688 · Cited by 138
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
Short, N. J., Jabbour, E. J., Albitar, M. X., Lima, M. J. G. D., Gore, L., Jorgensen, J. L., Logan, A. C., Park, J. H., Ravandi, F., Shah, B. D., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25338 · Cited by 140
Self-citation
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
Müller, Y. D., Nguyen, D., Ferreira, L. M. R., Ho, P., Raffin, C., Beltran, R. V., Congrave‐Wilson, Z., Roth, T. L., Eyquem, J., Gool, F. V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639818 · Cited by 146
Base-edited CAR T cells for combinational therapy against T cell malignancies
Georgiadis, C., Rasaiyaah, J., Gkazi, S. A., Preece, R., Etuk, A., Christi, A., & Qasim, W. (2021) · Leukemia · doi:10.1038/s41375-021-01282-6 · Cited by 140
Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
Mardiana, S., Solomon, B., Darcy, P. K., & Beavis, P. A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2293 · Cited by 140
Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients
Arcangeli, S., Falcone, L., Camisa, B., De Girardi, F., Biondi, M., Giglio, F., Ciceri, F., Bonini, C., Bondanza, A., & Casucci, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01217 · Cited by 134
In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 140
Myeloid cell–targeted miR-146a mimic inhibits NF-κB–driven inflammation and leukemia progression in vivo
Su, Y., Wang, X., Mann, M., Adamus, T., Wang, D., Moreira, D., Zhang, Z., Ouyang, C., He, X., Zhang, B., et al. (2019) · Blood · doi:10.1182/blood.2019002045 · Cited by 135
Self-citation
Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions
Wat, J., & Barmettler, S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.10.037 · Cited by 137
CAR T cell therapy in solid tumors: A review of current clinical trials
Patel, U., Abernathy, J., Savani, B. N., Oluwole, O. O., Sengsayadeth, S. M., & Dholaria, B. (2021) · eJHaem · doi:10.1002/jha2.356 · Cited by 133
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials
Leahy, A. B., Newman, H. M., Li, Y., Liu, H., Myers, R. M., DiNofia, A. M., Dolan, J. G., Callahan, C. A., Baniewicz, D., Devine, K. J., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00238-6 · Cited by 133
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Katsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1962 · Cited by 131
Self-citation
Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment
Wang, N., Li, X., Wang, R., & Ding, Z. (2021) · Biotechnology Journal · doi:10.1002/biot.202100041 · Cited by 136
Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy
Yoshikawa, T., Wu, Z., Inoue, S., Kasuya, H., Matsushita, H., Takahashi, Y., Kuroda, H., Hosoda, W., Suzuki, S., & Kagoya, Y. (2021) · Blood · doi:10.1182/blood.2021012714 · Cited by 134
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
Anagnostou, T., Riaz, I. B., Hashmi, S. K., Murad, M. H., & Kenderian, S. S. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30277-5 · Cited by 132
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation
Liu, S., Deng, B., Yin, Z., Lin, Y., An, L., Liu, D., Pan, J., Yu, X., Chen, B., Wu, T., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26160 · Cited by 131
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Gauthier, J., & Turtle, C. J. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.003 · Cited by 131
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J. W., Mei, H., & Hu, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03685-z · Cited by 132
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Winer, E. S., & Stone, R. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719860645 · Cited by 133
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128
Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma
Wang, J., Hu, Y., Yang, S., Wei, G., Zhao, X., Wu, W., Zhang, Y., Zhang, Y., Chen, D., Wu, Z., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.02.008 · Cited by 130
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
Rabilloud, T., Potier, D., Pankaew, S., Nozais, M., Loosveld, M., & Payet‐Bornet, D. (2021) · Nature Communications · doi:10.1038/s41467-021-21168-6 · Cited by 133
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai, Z., Feng, B., McClory, S., de Oliveira, B. C., Diorio, C. J., Grégoire, C., Tao, B., Yang, L., Zhao, Z., Peng, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07762-w · Cited by 128
Harnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 133
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Cui, Q., Qian, C., Xu, N., Kang, L., Dai, H., Cui, W., Song, B., Yin, J., Li, Z., Zhu, X., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01092-4 · Cited by 128
Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
Zhao, X., Yang, J., Zhang, X., Lu, X., Xiong, M., Zhang, J., Zhou, X., Qi, F., He, T., Ding, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.016 · Cited by 132
BiTEs better than CAR T cells
Subklewe, M. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001792 · Cited by 130
Immune cell therapy for hepatocellular carcinoma
Mizukoshi, E., & Kaneko, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0742-5 · Cited by 126
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
Maldini, C. R., Claiborne, D. T., Okawa, K., Chen, T., Dopkin, D. L., Shan, X., Power, K. A., Trifonova, R. T., Krupp, K. L., Phelps, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1039-5 · Cited by 125
Reactions Related to CAR-T Cell Therapy
Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663201 · Cited by 129
Born to survive: how cancer cells resist CAR T cell therapy
Lemoine, J., Ruella, M., & Houot, R. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01209-9 · Cited by 126
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Caruso, S., Angelis, B. D., Bufalo, F. D., Ciccone, R., Donsante, S., Volpe, G., Manni, S., Guercio, M., Pezzella, M., Iaffaldano, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01376-3 · Cited by 126
Telomerase-Targeted Cancer Immunotherapy
Mizukoshi, E., & Kaneko, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081823 · Cited by 129
Immunotherapy in pediatric acute lymphoblastic leukemia
Inaba, H., & Pui, C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09834-0 · Cited by 129
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Siddiqi, T., Soumerai, J. D., Dorritie, K. A., Stephens, D. M., Riedell, P. A., Arnason, J. E., Kipps, T. J., Gillenwater, H. H., Gong, L., Yang, L., et al. (2021) · Blood · doi:10.1182/blood.2021011895 · Cited by 126
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Haubner, S., Mansilla‐Soto, J., Nataraj, S. E., Kogel, F., Chang, Q., de Stanchina, E., Lopez, M. A., Ng, M. R., Fraser, K. A., Subklewe, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.010 · Cited by 125
Self-citation
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
Hadiloo, K., Taremi, S., Heidari, M., & Esmaeilzadeh, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00537-x · Cited by 128
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
Koehl, U., Arsenieva, S., Holzinger, A., & Abken, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.254 · Cited by 124
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Titov, A., Petukhov, A., Staliarova, A., Motorin, D., Bulatov, E., Shuvalov, O. Y., Soond, S. M., Piacentini, M., Melino, G., Zaritskey, A. Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0918-x · Cited by 124
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes
Holtzman, N. G., Xie, H., Bentzen, S. M., Kesari, V., Bukhari, A. A., Chaer, F. E., Lutfi, F. U., Siglin, J., Hutnick, E., Gahres, N., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa183 · Cited by 121
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E. L., Mavroukakis, S. A., Pacenta, H. L., Phillips, C. L., Rossoff, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006418 · Cited by 122
Self-citation
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Foà, R., & Chiaretti, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2113347 · Cited by 122
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Sterner, R. C., & Sterner, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879608 · Cited by 121
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Jabbour, E. J., Short, N. J., Jain, N., Haddad, F., Welch, M. A., Ravandi, F., & Kantarjian, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01409-5 · Cited by 123
Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis
Li, B., Zhang, B., Wang, X., Zeng, Z., Huang, Z., Zhang, L., Wei, F., Ren, X., & Yang, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1807291 · Cited by 118
Self-citation
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Rafei, H., Daher, M., & Rezvani, K. (2020) · British Journal of Haematology · doi:10.1111/bjh.17186 · Cited by 121
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Li, L., Mohanty, V., Dou, J., Huang, Y., Banerjee, P. P., Miao, Q., Lohr, J. G., Vijaykumar, T., Frede, J., Knoechel, B., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6997 · Cited by 120
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
Smith, E. L., Stæhr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.016 · Cited by 119
Self-citation
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
Jacoby, E., Bielorai, B., Avigdor, A., Itzhaki, O., Hutt, D., Nussboim, V., Meir, A., Kubi, A., Levy, M., Zikich, D., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25274 · Cited by 117
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0451-2 · Cited by 117
Self-citation
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
Martino, M. V., Alati, C., Canale, F. A., Musuraca, G., Martinelli, G., & Cerchione, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042150 · Cited by 120
Neurotoxicity after CTL019 in a pediatric and young adult cohort
Gofshteyn, J. S., Shaw, P. A., Teachey, D. T., Grupp, S. A., Maude, S. L., Banwell, B., Chen, F., Lacey, S. F., Melenhorst, J. J., Edmondson, M. J., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25315 · Cited by 119
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart
Ganatra, S., Carver, J. R., Hayek, S. S., Ky, B., Leja, M. J., Lenihan, D. J., Lenneman, C. G., Mousavi, N., Park, J. H., Perales, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.049 · Cited by 118
Self-citation
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy
Leahy, A. B., Devine, K. J., Li, Y., Liu, H., Myers, R. M., DiNofia, A. M., Wray, L., Rheingold, S. R., Callahan, C. A., Baniewicz, D., et al. (2021) · Blood · doi:10.1182/blood.2021012727 · Cited by 118
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
Müller, S. C., Bexte, T., Gebel, V., Kalensee, F., Stolzenberg, E., Hartmann, J., Koehl, U., Schambach, A., Wels, W. S., Modlich, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03123 · Cited by 120
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
Boissel, N., & Baruchel, A. (2018) · Blood · doi:10.1182/blood-2018-02-778530 · Cited by 117
Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL
Qi, Y., Zhao, M., Hu, Y., Wang, Y., Li, P., Cao, J., Shi, M., Tan, J., Zhang, M., Xiao, X., et al. (2022) · Blood · doi:10.1182/blood.2021013733 · Cited by 114
Self-citation
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
Yang, J., He, J., Zhang, X., Li, J., Wang, Z., Zhang, Y., Qiu, L., Wu, Q., Sun, Z., Ye, X., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00694-6 · Cited by 118
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
Singh, A. P., Zheng, X., Lin‐Schmidt, X., Chen, W., Carpenter, T. J., Zong, A., Wang, W., & Heald, D. (2019) · mAbs · doi:10.1080/19420862.2019.1688616 · Cited by 114
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 117
Cost of decentralized CAR T‐cell production in an academic nonprofit setting
Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33156 · Cited by 118
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
Jabbour, E. J., Sasaki, K., Ravandi, F., Huang, X., Short, N. J., Khouri, M., Kebriaei, P., Burger, J. A., Khoury, J. D., Jorgensen, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31720 · Cited by 114
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Vairy, S., Garcia, J. L., Teira, P., & Bittencourt, H. N. D. S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s138765 · Cited by 112
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Schmidts, A., Ormhøj, M., Choi, B. D., Taylor, A., Bouffard, A. A., Scarfò, I., Larson, R. C., Frigault, M. J., Gallagher, K., Castaño, A. P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000703 · Cited by 116
Recent advances in the treatment of acute lymphoblastic leukemia
Rafei, H., Kantarjian, H. M., & Jabbour, E. J. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1605071 · Cited by 114
CAR-T Cell Therapy: From the Shop to Cancer Therapy
Uscanga‐Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., Támez-Guerra, R., Rodrı́guez-Padilla, C., & Alcocer-González, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115688 · Cited by 116
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Kaufman, H. L., Atkins, M. B., Subedi, P., Wu, J. J., Chambers, J. D., Mattingly, T. J., Campbell, J. D., Allen, J., Ferris, A. E., Schilsky, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0594-0 · Cited by 112
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
Fischer, J. W., & Bhattarai, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693016 · Cited by 113
In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery
Ye, Z., Chen, J., Zhao, X., Li, Y., Harmon, J., Huang, C., Chen, J., & Xu, Q. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01532 · Cited by 110
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
Shah, P. D., Huang, A. C. C., Xu, X., Orlowski, R. J., Amaravadi, R. K., Schuchter, L. M., Zhang, P. J., Tchou, J. C., Matlawski, T., Cervini, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0486 · Cited by 112
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Choi, B. D., Maus, M. V., June, C. H., & Sampson, J. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1625 · Cited by 113
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu, Y., Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.12.001 · Cited by 112
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Zhao, J., Song, Y., & Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0705-x · Cited by 111
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells
Sanber, K. S., Savani, B. N., & Jain, T. (2021) · British Journal of Haematology · doi:10.1111/bjh.17544 · Cited by 111
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Cadilha, B. L., Benmebarek, M.-R., Dorman, K., Öner, A., Lorenzini, T., Obeck, H., Vänttinen, M., Pilato, M. D., Pruessmann, J. N., Stoiber, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi5781 · Cited by 111

Authors: Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
ORCID: Park, Jae H.
Rivière, Isabelle
Wang, Xiuyan
Sénéchal, Brigitte
Curran, Kevin J.
Sauter, Craig
Wang, Yongzeng
Santomasso, Bianca
Roshal, Mikhail
Maslak, Peter
Davila, Marco
Brentjens, Renier J.
Sadelain, Michel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-02
Volume: 378
Issue: 5
Pages: 449-459
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1709919
PMC: PMC6637939
OpenAlex: W2787621143
Cited by: 2,688
References: 24
Citations by year: 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
FWCI: 118.36
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Comprehensive Cancer Network Foundation (Young Investigator Award)
Emerald Foundation
National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
Leukemia and Lymphoma Society (Career Development Award)
American Society of Clinical Oncology (Career Development Award)
Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
Juno Therapeutics
Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
Stand Up To Cancer
William Lawrence and Blanche Hughes Foundation
Annual Terry Fox Run for Cancer Research
Carson Family Charitable Trust
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
MeSH terms: Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks